Ly3023414 (Not yet branded)
Other Medications
Description
LY3023414 is a dual PI3K/mTOR kinase inhibitor that targets multiple components of the PI3K/AKT/mTOR signaling pathway. In colorectal cancer treatment, it is particularly relevant for tumors harboring PIK3CA mutations, which occur in approximately 15-20% of CRC cases. The compound blocks both PI3K isoforms and mTOR kinase activity through a single agent, potentially offering enhanced pathway inhibition compared to selective inhibitors.
Mechanism of Action
LY3023414 functions as an ATP-competitive inhibitor that simultaneously targets class I PI3K isoforms ( , ?, ?, ?) and both mTORC1 and mTORC2 complexes. This dual inhibition disrupts critical cellular processes including protein synthesis, cell survival, proliferation, and metabolism that are often dysregulated in PIK3CA-mutated colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.